CA2322003A1 - Anticorps monoclonaux humains capables de reconnaitre de maniere oligospecifique les principaux gangliosides associes aux tumeurs, et leurs procedes d'utilisation - Google Patents

Anticorps monoclonaux humains capables de reconnaitre de maniere oligospecifique les principaux gangliosides associes aux tumeurs, et leurs procedes d'utilisation Download PDF

Info

Publication number
CA2322003A1
CA2322003A1 CA002322003A CA2322003A CA2322003A1 CA 2322003 A1 CA2322003 A1 CA 2322003A1 CA 002322003 A CA002322003 A CA 002322003A CA 2322003 A CA2322003 A CA 2322003A CA 2322003 A1 CA2322003 A1 CA 2322003A1
Authority
CA
Canada
Prior art keywords
antibody
seq
tumor
gangliosides
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002322003A
Other languages
English (en)
Inventor
Michael E. Mcknight
Mark C. Glassy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Viventia Bio Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2322003A1 publication Critical patent/CA2322003A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CA002322003A 1998-02-27 1999-02-26 Anticorps monoclonaux humains capables de reconnaitre de maniere oligospecifique les principaux gangliosides associes aux tumeurs, et leurs procedes d'utilisation Abandoned CA2322003A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US7620098P 1998-02-27 1998-02-27
US60/076,200 1998-02-27
PCT/CA1999/000178 WO1999043815A2 (fr) 1998-02-27 1999-02-26 Anticorps monoclonaux humains capables de reconnaitre de maniere oligospecifique les principaux gangliosides associes aux tumeurs, et leurs procedes d'utilisation

Publications (1)

Publication Number Publication Date
CA2322003A1 true CA2322003A1 (fr) 1999-09-02

Family

ID=22130549

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002322003A Abandoned CA2322003A1 (fr) 1998-02-27 1999-02-26 Anticorps monoclonaux humains capables de reconnaitre de maniere oligospecifique les principaux gangliosides associes aux tumeurs, et leurs procedes d'utilisation

Country Status (4)

Country Link
EP (1) EP1056861A2 (fr)
AU (1) AU3242799A (fr)
CA (1) CA2322003A1 (fr)
WO (1) WO1999043815A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050260206A1 (en) * 2001-03-29 2005-11-24 Kenya Shitara Drugs containing genetically modified antibody against ganglioside gd3
JP4473730B2 (ja) 2002-09-11 2010-06-02 シャーンタ ウェスト インコーポレーティッド 過剰増殖性細胞を認識する抗体ならびにその作製および使用方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4107154A1 (de) * 1990-10-11 1992-04-16 Boehringer Mannheim Gmbh Monoklonale antikoerper gegen melanom
US5419904A (en) * 1990-11-05 1995-05-30 The Regents Of The University Of California Human B-lymphoblastoid cell line secreting anti-ganglioside antibody
EP0492409A1 (fr) * 1990-12-18 1992-07-01 Ishihara Sangyo Kaisha, Ltd. Anticorps monoclonal humain

Also Published As

Publication number Publication date
AU3242799A (en) 1999-09-15
EP1056861A2 (fr) 2000-12-06
WO1999043815A3 (fr) 1999-11-25
WO1999043815A2 (fr) 1999-09-02

Similar Documents

Publication Publication Date Title
KR101683884B1 (ko) 항-ＥｐＣＡＭ 항체 및 이의 용도
JP6082673B2 (ja) 特異的結合タンパク質およびその使用
EP3728324B1 (fr) Anticorps dirigés contre des antigènes de tumeur
EP1765868B1 (fr) Anticorps contre le récepteur de transferrine
EP1467757B1 (fr) Utilisation d'anticorps diriges contre l'antigene muc18
EP1470146B1 (fr) Anticorps contre l'antigene muc18
AU2006210606B2 (en) Antibodies to Oncostatin M receptor
EP0721470B1 (fr) Anticorps monoclonaux utilises pour le diagnostic et le traitement du cancer colorectal
EP0699756B1 (fr) Anticorps BR96 mutantsréagissant aux carcinomes humains
BG62386B1 (bg) Метод за лечение на в-клетъчна лимфома
EP3746123A1 (fr) Anticorps dirigés contre la galectine-3 et leurs procédés d'utilisation
EP4209512A1 (fr) Développement d'un agent thérapeutique contenant un adaptateur et son utilisation
KR101442323B1 (ko) 항-연장된 ⅰ형 글라이코스핑고지질 항체, 이의 유도체 및 용도
CA2322003A1 (fr) Anticorps monoclonaux humains capables de reconnaitre de maniere oligospecifique les principaux gangliosides associes aux tumeurs, et leurs procedes d'utilisation
EP4299591A1 (fr) Préparation de protéine de liaison de siglec-15 et son utilisation
US20240043568A1 (en) Development of new tumor engager therapeutic drug and use thereof
US20240190955A1 (en) Composition comprising an ige antibody
US20200055952A1 (en) Antibodies Against Carcinoembryonic Antigen for Cancer Therapy and Diagnosis

Legal Events

Date Code Title Description
FZDE Discontinued